Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTZPWGN)

• DTT Name: Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) DTT Info
• Gene Name: CACNA1H

Molecule-Related Drug & Molecule List

2 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flunarizine	DMZU5JP	Migraine	8A80	Approved	[1]
Sodium bicarbonate	DMMU6BJ	Metabolic acidosis	5C73	Approved	[2]

2 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ABT-639	DMEWQ4X	Pain	MG30-MG3Z	Phase 2	[3]
Mibefradil	DMU9VDS	Glioblastoma multiforme	2A00.0	Phase 1	[4]

1 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TTA-A8	DMWZCIF	Insomnia	7A00-7A0Z	Preclinical	[5]

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
U-92032	DMTYO3P	N. A.	N. A.	Terminated	[6]

16 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cis-N,5-dibenzyl-6-oxomorpholine-3-carboxamide	DM75SO4	Discovery agent	N.A.	Investigative	[7]
DP-3005	DMXEVA2	Angina pectoris	BA40	Investigative	[8]
GNF-PF-1967	DMGSRLA	Discovery agent	N.A.	Investigative	[9]
GNF-PF-4599	DM1ZMUN	Discovery agent	N.A.	Investigative	[9]
HYP-10	DMW9HTL	Pain	MG30-MG3Z	Investigative	[8]
KST-5468	DMT0CR5	Pain	MG30-MG3Z	Investigative	[8]
KYS-05001	DM3MID9	Discovery agent	N.A.	Investigative	[10]
KYS-05040	DM1JU8F	Discovery agent	N.A.	Investigative	[10]
KYS-05041	DMVA6LH	Discovery agent	N.A.	Investigative	[10]
KYS-05042	DMM6G4H	Discovery agent	N.A.	Investigative	[10]
KYS-05050	DMXR3V4	Solid tumour/cancer	2A00-2F9Z	Investigative	[11]
KYS-05077	DMHW40F	Discovery agent	N.A.	Investigative	[11]
KYS-05080	DM57BXZ	Discovery agent	N.A.	Investigative	[11]
ML218	DM3D21X	Discovery agent	N.A.	Investigative	[12]
TTL-1177	DMDM7C6	Solid tumour/cancer	2A00-2F9Z	Investigative	[8]
Z 944	DMFT51X	Discovery agent	N.A.	Investigative	[13]

References

• [1] Positive allosteric interaction of structurally diverse T-type calcium channel antagonists. Cell Biochem Biophys. 2009;55(2):81-93.
• [2] Acute renal failure. Clin Evid (Online). 2008 Sep 3;2008. pii: 2001.
• [3] Effects of a T-type calcium channel blocker, ABT-639, on spontaneous activity in C-nociceptors in patients with painful diabetic neuropathy: a randomized controlled trial. Pain. 2015 Nov;156(11):2175-83.
• [4] Mibefradil block of cloned T-type calcium channels. J Pharmacol Exp Ther. 2000 Oct;295(1):302-8.
• [5] Short-acting T-type calcium channel antagonists significantly modify sleep architecture in rodents. ACS Med Chem Lett. 2010 Aug 24;1(9):504-9.
• [6] Discovery of (2S)-1-(4-amino-2,3,5- trimethylphenoxy)-3-[4-[4-(4- fluorobenzyl)phenyl]-1-piperazinyl]-2-propanol dimethanesulfonate (SUN N8075): a ... J Med Chem. 2000 Sep 7;43(18):3372-6.
• [7] Morpholin-2-one derivatives as novel selective T-type Ca2+ channel blockers. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5244-8.
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 536).
• [9] 3D pharmacophore based virtual screening of T-type calcium channel blockers. Bioorg Med Chem. 2007 Jan 15;15(2):1091-105.
• [10] 3,4-Dihydroquinazoline derivatives as novel selective T-type Ca2+ channel blockers. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3379-84.
• [11] Synthesis and biological evaluation of novel T-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Jan 15;17(2):471-5.
• [12] The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's Disease. ACS Chem Neurosci. 2011 Dec 21;2(12):730-742.
• [13] Z944, a Novel Selective T-Type Calcium Channel Antagonist Delays the Progression of Seizures in the Amygdala Kindling Model.PLoS One.2015 Aug 14;10(8):e0130012.